RT Journal Article
SR Electronic
T1 2022-RA-1008-ESGO The impact of cytoreductive surgery in FIGO IV and recurrent endometrial cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A129
OP A129
DO 10.1136/ijgc-2022-ESGO.277
VO 32
IS Suppl 2
A1 Aleksandra Natalia Strojna
A1 Beyhan Ataseven
A1 Florian Heitz
A1 Nicole Concin
A1 Malak Moubarak
A1 Timo Westermann
A1 Sabrina Kaiser
A1 Nina Pauly
A1 Timoleon Dagres
A1 Vasileios Vrentas
A1 Andreas du Bois
A1 Alexander Traut
A1 Philipp Harter
YR 2022
UL http://ijgc.bmj.com/content/32/Suppl_2/A129.2.abstract
AB Introduction/Background The aim of the study was to assess the oncological outcomes of cytoreductive surgery in FIGO IV and recurrent endometrial cancer.Methodology This is a retrospective, observational, single-center cohort study including patients with endometrial cancer FIGO IV stage disease undergoing primary cytoreductive surgery and recurrent endometrial cancer treated with secondary cytoreductive surgery between January 1999 and April 2022.Results 115 patients were included in the present study. In the 53 patients with primary FIGO IV disease complete macroscopic resection was achieved in 42/53 (79.2%) cases. Median OS in these patients was 35 months and median PFS was 15 months. Sixty-two patients had cytoreductive surgery for relapsed endometrial cancer and complete macroscopic resection was achieved in 82.2%. Median OS in this population was 28 months and median PFS was 8.2 months. Patients with complete macroscopic resection showed longer progression-free survival (PFS) and overall survival (OS) compared to those with residual disease (PFS: 15.1 vs 12.9 months; p=0,189; OS: 32.4 vs 17 months; p=0,130). Median OS was 44.6 months (95 % CI 24,6- 64,6 months) in endometrioid subtype (72/115 pts) and 27.4 months (95 %CI 7.2–47.6 months) in other histotypes (p=0.114). Major complications (>Clavien Dindo IIIB) were noted in 10/115 pts (8.7%), mortality rate was 0.9%.Conclusion Complete macroscopic resection is feasible in selected patients with FIGO IV and relapsed endometrial cancer with an acceptable morbidity, and seemed to be related to superior outcome. However, its impact on prognosis should be further evaluated.